SCM
CC icon

Salem Capital Management’s Chemours CC Stock Holding History

Salem Capital Management’s Portfolio CC Stock Details CC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-16,477
Closed -$107K – 66
2015
Q3 		$107K Buy
+16,477
New +$172K 0.06% 66

Other funds holding CC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CCM
Conatus Capital Management Greenwich, Connecticut $92.3M AUM 45.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Salem Capital Management's CC Position: Q4 2015 in Review

Salem Capital Management sold out of Chemours (CC) in Q4 2015, closing a stake of 16,477 shares — an estimated $107K sold.

Salem Capital Management first reported a position in CC in Q3 2015 and held it in 1 quarter. The position peaked at $107K in Q3 2015. 438 funds tracked by Wall St. Rank hold CC as of Q4 2015.

  • Salem Capital Management reported no remaining Chemours position as of Q4 2015 after selling out during the quarter.
  • Salem Capital Management sold 16,477 Chemours shares in Q4 2015, an estimated $107K.
  • Salem Capital Management first reported a position in Chemours in Q3 2015 and held it in 1 quarter.
  • Salem Capital Management's Chemours position peaked at $107K in Q3 2015.
  • 438 funds tracked by Wall St. Rank held Chemours as of Q4 2015.

Based on Salem Capital Management's 13F filing for Q4 2015, filed 21 Jan 2016.